Cargando…

Experimental Comparison of Fiducial Markers Used in Proton Therapy: Study of Different Imaging Modalities and Proton Fluence Perturbations Measured With CMOS Pixel Sensors

Fiducial markers are used for image guidance to verify the correct positioning of the target for the case of tumors that can suffer interfractional motion during proton therapy. The markers should be visible on daily imaging, but at the same time, they should produce minimal streak artifacts in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Reidel, Claire-Anne, Horst, Felix, Schuy, Christoph, Jäkel, Oliver, Ecker, Swantje, Henkner, Katrin, Brons, Stephan, Durante, Marco, Weber, Uli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990863/
https://www.ncbi.nlm.nih.gov/pubmed/35402273
http://dx.doi.org/10.3389/fonc.2022.830080
_version_ 1784683466748592128
author Reidel, Claire-Anne
Horst, Felix
Schuy, Christoph
Jäkel, Oliver
Ecker, Swantje
Henkner, Katrin
Brons, Stephan
Durante, Marco
Weber, Uli
author_facet Reidel, Claire-Anne
Horst, Felix
Schuy, Christoph
Jäkel, Oliver
Ecker, Swantje
Henkner, Katrin
Brons, Stephan
Durante, Marco
Weber, Uli
author_sort Reidel, Claire-Anne
collection PubMed
description Fiducial markers are used for image guidance to verify the correct positioning of the target for the case of tumors that can suffer interfractional motion during proton therapy. The markers should be visible on daily imaging, but at the same time, they should produce minimal streak artifacts in the CT scans for treatment planning and induce only slight dose perturbations during particle therapy. In this work, these three criteria were experimentally investigated at the Heidelberg Ion Beam Therapy Center. Several small fiducial markers with different geometries and materials (gold, platinum, and carbon-coated ZrO(2)) were evaluated. The streak artifacts on treatment planning CT were measured with and without iMAR correction, showing significantly smaller artifacts from markers lighter than 6 mg and a clear improvement with iMAR correction. Daily imaging as X-ray projections and in-room mobile CT were also performed. Markers heavier than 6 mg showed a better contrast in the X-ray projections, whereas on the images from the in-room mobile CT, all markers were clearly visible. In the other part of this work, fluence perturbations of proton beams were measured for the same markers by using a tracker system of several high spatial resolution CMOS pixel sensors. The measurements were performed for single-energy beams, as well as for a spread-out Bragg peak. Three-dimensional fluence distributions were computed after reconstructing all particle trajectories. These measurements clearly showed that the ZrO(2) markers and the low-mass gold/platinum markers (0.35mm diameter) induce perturbations being 2–3 times lower than the heavier gold or platinum markers of 0.5mm diameter. Monte Carlo simulations, using the FLUKA code, were used to compute dose distributions and showed good agreement with the experimental data after adjusting the phase space of the simulated proton beam compared to the experimental beam.
format Online
Article
Text
id pubmed-8990863
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89908632022-04-09 Experimental Comparison of Fiducial Markers Used in Proton Therapy: Study of Different Imaging Modalities and Proton Fluence Perturbations Measured With CMOS Pixel Sensors Reidel, Claire-Anne Horst, Felix Schuy, Christoph Jäkel, Oliver Ecker, Swantje Henkner, Katrin Brons, Stephan Durante, Marco Weber, Uli Front Oncol Oncology Fiducial markers are used for image guidance to verify the correct positioning of the target for the case of tumors that can suffer interfractional motion during proton therapy. The markers should be visible on daily imaging, but at the same time, they should produce minimal streak artifacts in the CT scans for treatment planning and induce only slight dose perturbations during particle therapy. In this work, these three criteria were experimentally investigated at the Heidelberg Ion Beam Therapy Center. Several small fiducial markers with different geometries and materials (gold, platinum, and carbon-coated ZrO(2)) were evaluated. The streak artifacts on treatment planning CT were measured with and without iMAR correction, showing significantly smaller artifacts from markers lighter than 6 mg and a clear improvement with iMAR correction. Daily imaging as X-ray projections and in-room mobile CT were also performed. Markers heavier than 6 mg showed a better contrast in the X-ray projections, whereas on the images from the in-room mobile CT, all markers were clearly visible. In the other part of this work, fluence perturbations of proton beams were measured for the same markers by using a tracker system of several high spatial resolution CMOS pixel sensors. The measurements were performed for single-energy beams, as well as for a spread-out Bragg peak. Three-dimensional fluence distributions were computed after reconstructing all particle trajectories. These measurements clearly showed that the ZrO(2) markers and the low-mass gold/platinum markers (0.35mm diameter) induce perturbations being 2–3 times lower than the heavier gold or platinum markers of 0.5mm diameter. Monte Carlo simulations, using the FLUKA code, were used to compute dose distributions and showed good agreement with the experimental data after adjusting the phase space of the simulated proton beam compared to the experimental beam. Frontiers Media S.A. 2022-03-25 /pmc/articles/PMC8990863/ /pubmed/35402273 http://dx.doi.org/10.3389/fonc.2022.830080 Text en Copyright © 2022 Reidel, Horst, Schuy, Jäkel, Ecker, Henkner, Brons, Durante and Weber https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Reidel, Claire-Anne
Horst, Felix
Schuy, Christoph
Jäkel, Oliver
Ecker, Swantje
Henkner, Katrin
Brons, Stephan
Durante, Marco
Weber, Uli
Experimental Comparison of Fiducial Markers Used in Proton Therapy: Study of Different Imaging Modalities and Proton Fluence Perturbations Measured With CMOS Pixel Sensors
title Experimental Comparison of Fiducial Markers Used in Proton Therapy: Study of Different Imaging Modalities and Proton Fluence Perturbations Measured With CMOS Pixel Sensors
title_full Experimental Comparison of Fiducial Markers Used in Proton Therapy: Study of Different Imaging Modalities and Proton Fluence Perturbations Measured With CMOS Pixel Sensors
title_fullStr Experimental Comparison of Fiducial Markers Used in Proton Therapy: Study of Different Imaging Modalities and Proton Fluence Perturbations Measured With CMOS Pixel Sensors
title_full_unstemmed Experimental Comparison of Fiducial Markers Used in Proton Therapy: Study of Different Imaging Modalities and Proton Fluence Perturbations Measured With CMOS Pixel Sensors
title_short Experimental Comparison of Fiducial Markers Used in Proton Therapy: Study of Different Imaging Modalities and Proton Fluence Perturbations Measured With CMOS Pixel Sensors
title_sort experimental comparison of fiducial markers used in proton therapy: study of different imaging modalities and proton fluence perturbations measured with cmos pixel sensors
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990863/
https://www.ncbi.nlm.nih.gov/pubmed/35402273
http://dx.doi.org/10.3389/fonc.2022.830080
work_keys_str_mv AT reidelclaireanne experimentalcomparisonoffiducialmarkersusedinprotontherapystudyofdifferentimagingmodalitiesandprotonfluenceperturbationsmeasuredwithcmospixelsensors
AT horstfelix experimentalcomparisonoffiducialmarkersusedinprotontherapystudyofdifferentimagingmodalitiesandprotonfluenceperturbationsmeasuredwithcmospixelsensors
AT schuychristoph experimentalcomparisonoffiducialmarkersusedinprotontherapystudyofdifferentimagingmodalitiesandprotonfluenceperturbationsmeasuredwithcmospixelsensors
AT jakeloliver experimentalcomparisonoffiducialmarkersusedinprotontherapystudyofdifferentimagingmodalitiesandprotonfluenceperturbationsmeasuredwithcmospixelsensors
AT eckerswantje experimentalcomparisonoffiducialmarkersusedinprotontherapystudyofdifferentimagingmodalitiesandprotonfluenceperturbationsmeasuredwithcmospixelsensors
AT henknerkatrin experimentalcomparisonoffiducialmarkersusedinprotontherapystudyofdifferentimagingmodalitiesandprotonfluenceperturbationsmeasuredwithcmospixelsensors
AT bronsstephan experimentalcomparisonoffiducialmarkersusedinprotontherapystudyofdifferentimagingmodalitiesandprotonfluenceperturbationsmeasuredwithcmospixelsensors
AT durantemarco experimentalcomparisonoffiducialmarkersusedinprotontherapystudyofdifferentimagingmodalitiesandprotonfluenceperturbationsmeasuredwithcmospixelsensors
AT weberuli experimentalcomparisonoffiducialmarkersusedinprotontherapystudyofdifferentimagingmodalitiesandprotonfluenceperturbationsmeasuredwithcmospixelsensors